Company / Cost of Revenue
PTC Therapeutics, Inc. Cost of Revenue History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$12.1M
FY2019
5-year range
-
FY2016-FY2019
Trend
-4.2%
vs FY2018
Sector context
#71 of 85
Health Care
What the data says
PTC Therapeutics, Inc.'s cost of revenue of $12M is lower than 84% of companies in the Health Care sector (FY2019). Increased from $5M to $12M over the past 2 years.
Based on SEC 10-K filings.
$12M in FY2019.
Increased from $5M to $12M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 85This company $12.1M Sector average $2.0B
▼
-99.4% below sector average
Key checks
Key Insights
- In FY2019, cost of revenue decreased 4.2% year-over-year.
- Ranks #71 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $12.1M | -4.2% |
| FY2018 | $12.7M | +176.8% |
| FY2017 | $4.6M | - |
| FY2016 | $0 | - |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026